Associated tags: KZR-261, Oncology, COVID-19, TIS, Inflammation, Disclosure, Muscle, Patient, Health, Cell, PM, Skin, Safety, Pharmaceutical industry, Mortality, Construction, Vaccine, Lupus Nephritis, Dermatomyositis and Polymyositis, Inhibition of Protein Secretion
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Dermatomyositis,
COVID-19,
Forward-looking statement,
Private Securities Litigation Reform Act,
Interim,
Mortality,
U.S. Securities and Exchange Commission,
Myopathy,
Polymyositis,
Safety,
Patient,
Autoimmune disease,
Immunosuppression,
TIS,
Lupus nephritis,
Inflammation,
Degenerative disease,
Skin,
Face,
OLE,
Respiration,
PRR,
Association,
Disease,
PM,
CEO,
Sec61,
Muscle,
Pharmaceutical industry,
Kezar Stadium No additional safety or tolerability issues have been observed, and mean TIS scores have improved over scores observed at the 32-week conclusion of PRESIDIO.
Key Points:
- No additional safety or tolerability issues have been observed, and mean TIS scores have improved over scores observed at the 32-week conclusion of PRESIDIO.
- The company plans to report the MISSION Phase 2 topline data in lupus nephritis (LN) at a Kezar corporate event in June 2022.
- In addition to PRESIDIO, Kezar is conducting the MISSION Phase 2 trial in patients with lupus nephritis.
- Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis.
Oncology,
Health,
Infectious Diseases,
Other Health,
Pharmaceutical,
Biotechnology,
Private Securities Litigation Reform Act,
Risk,
SLE,
Biomarker,
Degenerative disease,
Research,
Association,
International,
Lupus nephritis,
Disease,
Dialysis,
Dermatomyositis,
Diagnosis,
Immunosuppression,
American Association,
UPCR,
Annual general meeting,
International nonproprietary name,
U.S. Securities and Exchange Commission,
List of life sciences,
Respiration,
Autoimmunity,
Chronic kidney disease,
Forward-looking statement,
Death,
Clinical trial,
Pharmacokinetics,
Mortality,
Myopathy,
Kezar Pavilion,
AACR,
TIS,
Inflammation,
Disclosure,
American Association for Cancer Research,
Muscle,
Drug discovery,
INN,
Patient,
Total,
Cell,
PM,
Skin,
Tumor microenvironment,
Proteinuria,
Safety,
Data collection,
COVID-19,
Sec61,
Pharmaceutical industry,
Construction,
Vaccine,
LN,
Polymyositis,
Zetomipzomib (KZR-616),
KZR-261,
Lupus Nephritis,
Dermatomyositis and Polymyositis,
Inhibition of Protein Secretion,
Kezar Life Sciences,
ZETOMIPZOMIB (KZR-616),
KZR-261,
LUPUS NEPHRITIS,
DERMATOMYOSITIS AND POLYMYOSITIS,
INHIBITION OF PROTEIN SECRETION,
KEZAR LIFE SCIENCES Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
Key Points:
- Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
- The MISSION Phase 2 open-label trial in patients with active, proliferative LN reached target enrollment of 20 patients in November 2021.
- Research and development expenses for the fourth quarter of 2021 increased by $1.7 million to $9.8 million compared to $8.1 million in the fourth quarter of 2020.
- General and administrative expenses for the fourth quarter of 2021 increased by $1.3 million to $4.3 million compared to $3.0 million in the fourth quarter of 2020.
Retrieved on:
Tuesday, November 9, 2021
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Oncology,
Mortality,
Safety,
Associate,
Private Securities Litigation Reform Act,
SLE,
Chronic kidney disease,
MD,
Ohio State University,
Cytokine,
Investor relations,
U.S. Securities and Exchange Commission,
Endoplasmic reticulum,
Disease,
PM,
Lupus nephritis,
Inflammation,
Muscle,
COVID-19,
Dermatomyositis,
Research,
Ohio,
Forward-looking statement,
Total,
Dialysis,
List of life sciences,
Association,
Foreign policy,
Protein,
Myopathy,
TIS,
Disclosure,
Therapy,
Degenerative disease,
Pharmacokinetics,
Diagnosis,
Death,
Ohio State University Wexner Medical Center,
Public relations,
ATM,
Skin,
Cell,
UPCR,
Patient,
Immunosuppression,
Risk,
Respiration,
IND,
Pharmaceutical industry,
Construction,
Vaccine,
KZR-616,
KZR-261,
Lupus Nephritis,
Dermatomyositis and Polymyositis,
Inhibition of Protein Secretion,
Kezar Life Sciences,
KZR-616,
KZR-261,
LUPUS NEPHRITIS,
DERMATOMYOSITIS AND POLYMYOSITIS,
INHIBITION OF PROTEIN SECRETION,
KEZAR LIFE SCIENCES Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Key Points:
- Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.
- Kezar expects to report topline data in the second quarter of 2022.
- Kezar expects to report topline data in the second quarter of 2022.
- Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Retrieved on:
Thursday, August 12, 2021
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
KZR-616,
KZR-261,
Lupus Nephritis,
Dermatomyositis and Polymyositis,
Kezar Life Sciences,
KZR-616,
KZR-261,
LUPUS NEPHRITIS,
DERMATOMYOSITIS AND POLYMYOSITIS,
KEZAR LIFE SCIENCES Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2021 financial results and corporate highlights.
Key Points:
- Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2021 financial results and corporate highlights.
- Research and development expenses for the second quarter of 2021 increased by $2.2 million to $9.3 million compared to $7.1 million in the second quarter of 2020.
- General and administrative expenses for the second quarter of 2021 increased by $1.0 million to $3.7 million compared to $2.7 million in the second quarter of 2020.
- Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
Biotechnology,
Health,
Pharmaceutical,
Clinical trials,
Oncology,
Branches of biology,
Apoptosis,
Organelles,
Proteasome,
Proteins,
Cell biology,
KZR-616,
KZR-261,
Lupus Nephritis,
Dermatomyositis and Polymyositis,
Kezar Life Sciences,
KZR-616,
KZR-261,
LUPUS NEPHRITIS,
DERMATOMYOSITIS AND POLYMYOSITIS,
KEZAR LIFE SCIENCES (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its first quarter 2021 financial results and corporate highlights.\n\xe2\x80\x9cLast quarter saw excellent execution by the Kezar team across both of our programs.
Key Points:
- (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its first quarter 2021 financial results and corporate highlights.\n\xe2\x80\x9cLast quarter saw excellent execution by the Kezar team across both of our programs.
- The Phase 1 clinical trial will evaluate pharmacokinetics, safety, and tolerability in patients with solid tumors as well as preliminary signs of efficacy in tumor-specific expansion cohorts.
- Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression.
- Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\n'
Biotechnology,
FDA,
Health,
General Health,
Pharmaceutical,
Oncology,
Other Science,
Research,
Genetics,
Science,
Clinical trials,
KZR-616,
KZR-261,
Lupus Nephritis,
Dermatomyositis and Polymyositis,
Kezar Life Sciences (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its fourth quarter and year end 2020 financial results and corporate highlights.
Key Points:
- (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its fourth quarter and year end 2020 financial results and corporate highlights.
- In November 2020, additional data from this study were presented at the American College of Rheumatology Annual Meeting ( ACR Convergence 2020).
- Research and development expenses for the fourth quarter of 2020 increased by $0.7 million to $8.1 million compared to $7.4 million in the fourth quarter of 2019.
- General and administrative expenses for the fourth quarter of 2020 increased by $0.4 million to $3.0 million compared to $2.6 million in the fourth quarter of 2019.
